amiselimod vs ozanimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline
amiselimod
Developed by Bausch Health under a licence from Tanabe Pharma Corporation
NCT04857112 · Phase 2 · completed
This trial randomly assigned 322 people with ulcerative colitis to one of two amiselimod doses or placebo, with participants and investigators unaware of assignment. The primary measure was change in the modified Mayo Score, which combines the appearance of the bowel lining at endoscopy with clinical disease activity. Scores fell by 2.3 points on amiselimod against 1.6 points on placebo (p=0.002).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Change from Baseline in the modified Mayo Score at Day 85 (Baseline to Day 85): Change from baseline in modified Mayo Score at Day 85: amiselimod -2.3 vs placebo -1.6 (p=0.002) (met)
Result source: NCT04857112
ozanimod · Zeposia
Marketed by Bristol-Myers Squibb and partners
NCT02435992 · Phase 3 · completed
Randomized, quadruple-blinded, placebo-controlled, large adequately powered Phase 3 trial (n=1012) with a hard clinical/endoscopic remission endpoint that achieved statistical significance in the favorable direction at both induction and maintenance timepoints, satisfying the 'strong' definition.
Next expected readout: July 2032 · NCT05076175 (registry estimate)
Reported efficacy
Percentage of Participants in Clinical Remission at 10 Weeks; Percentage of Participants in Clinical Remission at 52 Weeks: Percentage of Participants in Clinical Remission at 10 Weeks (At 10 Weeks): RPC1063 Cohort 1(Induction Period) 18.4% vs Placebo Cohort 1 (Induction Period) 6.0% vs RPC1063 Cohort 2 (Induction Period) 21.0%; p=0.0001 (RPC1063 Cohort 1(Induction Period) vs Placebo Cohort 1 (Induction Period)) (met)
Result source: NCT02435992
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | amiselimod | ozanimod |
|---|---|---|
| Clinical remission (induction) | —Not reported | 18.4% vs 6%+12.4 vs placeboNCT024359923 other results
|
| Clinical remission (maintenance) | —Not reported | 37% vs 18.5%+18.5 vs placeboNCT024359922 other results
|
| Clinical response (induction) | —Not reported | 47.8% vs 25.9%+21.9 vs placeboNCT024359923 other results
|
| Endoscopic improvement (induction) | —Not reported | 27.3% vs 11.6%+15.7 vs placeboNCT024359923 other results
|
| Corticosteroid-free remission (maintenance) | —Not reported | 31.7% vs 16.7%+15 vs placeboNCT02435992 |
Clinical remission (induction)
- amiselimod
- —Not reported
- ozanimod
- 18.4% vs 6%+12.4 vs placeboNCT02435992
3 other results
- 21% vs 6% NCT02435992
- 16.4% vs 6.2% NCT01647516
- 13.8% vs 6.2% NCT01647516
Clinical remission (maintenance)
- amiselimod
- —Not reported
- ozanimod
- 37% vs 18.5%+18.5 vs placeboNCT02435992
2 other results
- 20.9% vs 6.2% NCT01647516
- 26.2% vs 6.2% NCT01647516
Clinical response (induction)
- amiselimod
- —Not reported
- ozanimod
- 47.8% vs 25.9%+21.9 vs placeboNCT02435992
3 other results
- 52.6% vs 25.9% NCT02435992
- 56.7% vs 36.9% NCT01647516
- 53.8% vs 36.9% NCT01647516
Endoscopic improvement (induction)
- amiselimod
- —Not reported
- ozanimod
- 27.3% vs 11.6%+15.7 vs placeboNCT02435992
3 other results
- 27.2% vs 11.6% NCT02435992
- 34.3% vs 12.3% NCT01647516
- 27.7% vs 12.3% NCT01647516
Corticosteroid-free remission (maintenance)
- amiselimod
- —Not reported
- ozanimod
- 31.7% vs 16.7%+15 vs placeboNCT02435992
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. amiselimod: 0 of 4 rows · ozanimod: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | amiselimod | ozanimod |
|---|---|---|
| Dropout rate | — | —1mga NCT02435992 · Phase 3 · monotherapy show 15 more results—1mg NCT02435992 · Phase 3 · monotherapy —1mg NCT02435992 · Phase 3 · monotherapy —RPC1063 (Maintenance Period) NCT02435992 · Phase 3 · monotherapy 11.7%RPC1063 Cohort 2 (Induction Period NCT02435992 · Phase 3 · monotherapy 46.3%RPC01-202 Ozanimod Open Label NCT02531126 · Phase 3 · monotherapy 69.5%RPC01-3101 Ozanimod-Ozanimod NCT02531126 · Phase 3 · monotherapy —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 6%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg/1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 4.5%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —Open-Label Treatment Period (OLP): NCT01647516 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | — | —1mga NCT02435992 · Phase 3 · monotherapy show 15 more results—1mg NCT02435992 · Phase 3 · monotherapy —1mg NCT02435992 · Phase 3 · monotherapy —RPC1063 (Maintenance Period) NCT02435992 · Phase 3 · monotherapy 3.3%RPC1063 Cohort 2 (Induction Period NCT02435992 · Phase 3 · monotherapy 7.4%RPC01-202 Ozanimod Open Label NCT02531126 · Phase 3 · monotherapy 6.1%RPC01-3101 Ozanimod-Ozanimod NCT02531126 · Phase 3 · monotherapy —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 0%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg/1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 3%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence —Open-Label Treatment Period (OLP): NCT01647516 · Phase 2 · registry result, not featured evidence |
| Serious AEs | — | 4%1mga NCT02435992 · Phase 3 · monotherapy show 15 more results6.3%1mg NCT02435992 · Phase 3 · monotherapy 5.2%1mg NCT02435992 · Phase 3 · monotherapy —RPC1063 (Maintenance Period) NCT02435992 · Phase 3 · monotherapy —RPC1063 Cohort 2 (Induction Period NCT02435992 · Phase 3 · monotherapy 14.8%RPC01-202 Ozanimod Open Label NCT02531126 · Phase 3 · monotherapy 17.2%RPC01-3101 Ozanimod-Ozanimod NCT02531126 · Phase 3 · monotherapy 3%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 2.4%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 18.6%1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —1 mg NCT01647516 · Phase 2 · registry result, not featured evidence 1.5%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence 0%0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence 25%0.5 mg/1 mg NCT01647516 · Phase 2 · registry result, not featured evidence —0.5 mg NCT01647516 · Phase 2 · registry result, not featured evidence 9.1%Open-Label Treatment Period (OLP): NCT01647516 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | — | show 11 more resultscovid-19 25.9% (placebo 16.8%) lymphopenia 16.7% (placebo 17.3%) leukopenia 7.4% (placebo 4.1%) NCT02531126 · Phase 3 · monotherapy lymphopenia 16.3% (placebo 17.3%) covid-19 11.3% (placebo 16.8%) lymphocyte count decreased 10.8% (placebo 12.8%) NCT02531126 · Phase 3 · monotherapy 1 mg alanine aminotransferase increased 3% (placebo 0%) headache 3% (placebo 4.6%) anaemia 1.5% (placebo 6.2%) NCT01647516 · Phase 2 · registry result, not featured evidence 1 mg alanine aminotransferase increased 2.4% (placebo 0%) colitis ulcerative 2.4% (placebo 1.5%) anaemia 0% (placebo 6.2%) NCT01647516 · Phase 2 · registry result, not featured evidence 1 mg hypertension 11.9% (placebo 0%) gamma-glutamyltransferase increased 8.5% (placebo 0%) upper respiratory tract infection 8.5% (placebo 3.1%) NCT01647516 · Phase 2 · registry result, not featured evidence 0.5 mg anaemia 6.2% (placebo 6.2%) colitis ulcerative 3.1% (placebo 1.5%) back pain 1.5% (placebo 1.5%) NCT01647516 · Phase 2 · registry result, not featured evidence 0.5 mg alanine aminotransferase increased 2.8% (placebo 0%) nasopharyngitis 2.8% (placebo 0%) anaemia 0% (placebo 6.2%) NCT01647516 · Phase 2 · registry result, not featured evidence 0.5 mg/1 mg anaemia 5.4% (placebo 6.2%) gamma-glutamyltransferase increased 5.4% (placebo 0%) lymphocyte count decreased 5.4% (placebo 0%) NCT01647516 · Phase 2 · registry result, not featured evidence anaemia 7.3% (placebo 6.2%) colitis ulcerative 7.3% (placebo 1.5%) bronchitis 5.5% (placebo 0%) NCT01647516 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
amiselimod
ozanimod
show 6 more results
show 6 more results
show 6 more results
show 2 more results
show 4 more results
show 4 more results
show 9 more results
show 4 more results
show 9 more results
show 9 more results
+ 6 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: amiselimod's landscape · ozanimod's landscape